Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
基本信息
- 批准号:8068292
- 负责人:
- 金额:$ 30.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-06-01 至 2013-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAftercareAntibodiesAntibody TherapyAntigen TargetingAntigensAutologousBindingBiological AssayBiopsyBiotechnologyBloodCD4 Positive T LymphocytesCD8B1 geneCancer CenterCell DeathCellsClinicalComplementCytolysisCytotoxic T-LymphocytesDataDevelopmentDiseaseDoseDot ImmunoblottingEffectivenessEnvironmentEnzyme-Linked Immunosorbent AssayEpitopesFollicular LymphomaFrequenciesGranulocyte-Macrophage Colony-Stimulating FactorImmune responseImmune systemImmunoglobulin Variable RegionImmunoglobulinsIn VitroIndolentInduction of ApoptosisInflammatoryInstitutional Review BoardsInterleukin 2 ReceptorIntravenous infusion proceduresKnockout MiceKnowledgeLeadLightLymphocyteLymphomaMHC Class I GenesMS4A1 geneMalignant NeoplasmsMediatingMemoryModelingMolecularMonitorMonoclonal AntibodiesMonoclonal Antibody CD20Monoclonal Antibody TherapyMulticenter TrialsNatureNewly DiagnosedOligonucleotidesPassive ImmunotherapyPatientsPeptidesPeripheral Blood LymphocytePeripheral Blood Mononuclear CellProductionProteinsProtocols documentationPublishingQualifyingRefractoryRelapseResearch PersonnelSeminalSerumSpecimenSystemT cell responseT memory cellT-LymphocyteTestingTherapeuticTimeTissuesTumor AntigensWestern BlottingWorkantibody conjugateantibody-dependent cell cytotoxicitybaseclinical effectcytokinedesignin vivokillingslymph nodesneoplastic cellnovelnovel strategiesperipheral bloodprecursor cellresponserituximabtreatment strategytumor
项目摘要
DESCRIPTION (provided by applicant): Rituximab, a chimeric monoclonal antibody directed against CD20, has shown significant therapeutic activity in patients with follicular lymphoma (FL), yet it's exact mechanism of action has not been completely defined. Although killing of the CD20+ FL cells, either through complement dependent cytolysis, antibody dependent cellular cytotoxicity or direct induction of apoptosis may contribute to its effectiveness, these mechanisms are unlikely to be the only mechanisms of action as; (a) the clinical and molecular responses to Rituximab may continue for months after the last dose of Rituximab and; (b) the median duration of the second response to Rituximab is longer than that of the first response, clinical findings that cannot be explained solely by the mechanisms described above. Rituximab induced FL cell death is expected to result in the release of tumor antigens, for example antigens derived from the variable regions of the heavy (VH) and light chains (VL) of the FL associated immunoglobulin (Ig), and also as yet undefined tumor antigens, in a pro-inflammatory environment. We hypothesize that the Rituximab induced release of lymphoma-associated antigens will provoke a cell-mediated lymphoma specific immune response. We will test this hypothesis by monitoring newly diagnosed FL patients for the presence of both peripheral blood and tumor infitrating lymphoma specific effector and/or memory CD4+ and CD8+ T-cells, before and after Rituximab treatment using Elispot, Fluorispot, Lysispot and intracellular cytokine flow cytometric assays. We will also test two corollaries of this hypothesis, being that a Rituximab elicited active lymphoma specific cellular response would; (a) result in an increase in the effector functions of both the lymphoma-specific CD4+ and CD8+ T cells; and (b) provide the necessary T- cell help required to generate lymphoma-specific humoral responses. The demonstration that Rituximab generates a lymphoma specific immune response, as well as the knowledge of the target antigens of the response would have profound implications as to how we optimally treat patients with FL. For example, it would suggest that combining Rituximab with agents which would be anticipated to augment the elicitation of a lymphoma specific T-cell response, such as GM-CSF, CpG oligonucleotides, and anti-CTLA-4 monoclonal antibodies, would be of potential clinical benefit. In addition, the results of this study should be applicable to antibody therapy of other malignancies, and as such, we anticipate that these studies will lead to novel treatment strategies designed to enhance the effectiveness of monoclonal antibody therapy for cancer in general. Follicular lymphoma (FL) is an indolent, but essentially incurable disease, however new treatments, including Rituximab therapy, are offering new hope for patients suffering with this disease. Rituximab is an antibody, which is a protein that targets another protein on the lymphoma cell, resulting in lymphoma cell death, however the exact mechanism(s) by which Rituximab destroys lymphoma cells is not yet clearly defined. Our group is determining whether Rituximab induces lymphoma cell death by stimulating the patient's own immune system to eradicate the disease, as a better understanding of how Rituximab works in patients with lymphoma will allow us to develop new approaches to treatment that we anticipate will lead to increased benefit for patients with this disease.
描述(由申请人提供):Rituximab是一种靶向CD20的嵌合单克隆抗体,在滤泡性淋巴瘤(FL)患者中显示出显著的治疗活性,但其确切的作用机制尚未完全确定。虽然通过补体依赖性细胞溶解、抗体依赖性细胞毒性或直接诱导凋亡杀死CD20+ FL细胞可能有助于其有效性,但这些机制不太可能是其唯一的作用机制,因为;(a)对利妥昔单抗的临床和分子反应可能在最后一剂利妥昔单抗后持续数月;(b)利妥昔单抗第二次应答的中位持续时间比第一次应答的中位持续时间长,临床结果不能仅用上述机制来解释。利妥昔单抗诱导的FL细胞死亡预计会导致肿瘤抗原的释放,例如来自FL相关免疫球蛋白(Ig)重链(VH)和轻链(VL)可变区域的抗原,以及在促炎环境中尚未确定的肿瘤抗原。我们假设,利妥昔单抗诱导淋巴瘤相关抗原的释放将引发细胞介导的淋巴瘤特异性免疫反应。我们将通过Elispot、Fluorispot、Lysispot和细胞内细胞因子流式细胞术检测,监测新诊断的FL患者外周血和肿瘤浸润性淋巴瘤特异性效应和/或记忆性CD4+和CD8+ t细胞的存在,来验证这一假设。我们还将检验这一假设的两个推论,即利妥昔单抗引发活动性淋巴瘤特异性细胞反应;(a)导致淋巴瘤特异性CD4+和CD8+ T细胞的效应功能增加;(b)提供产生淋巴瘤特异性体液反应所需的T细胞帮助。利妥昔单抗产生淋巴瘤特异性免疫反应的证明,以及对该反应的靶抗原的了解,将对我们如何最佳地治疗FL患者产生深远的影响。例如,它将表明,利妥昔单抗与预期会增强淋巴瘤特异性t细胞反应的药物联合使用,如GM-CSF、CpG寡核苷酸和抗ctla -4单克隆抗体。会有潜在的临床益处。此外,本研究的结果应该适用于其他恶性肿瘤的抗体治疗,因此,我们预计这些研究将导致新的治疗策略,旨在提高单克隆抗体治疗癌症的有效性。滤泡性淋巴瘤(滤泡性淋巴瘤)是一种惰性的,但基本上无法治愈的疾病,然而新的治疗方法,包括利妥昔单抗治疗,为患有这种疾病的患者带来了新的希望。利妥昔单抗是一种抗体,它是一种蛋白质,可以靶向淋巴瘤细胞上的另一种蛋白质,导致淋巴瘤细胞死亡,但利妥昔单抗破坏淋巴瘤细胞的确切机制尚不清楚。我们的团队正在确定Rituximab是否通过刺激患者自身免疫系统来诱导淋巴瘤细胞死亡,以根除疾病,因为更好地了解Rituximab如何在淋巴瘤患者中起作用,将使我们能够开发新的治疗方法,我们预计将为这种疾病患者带来更多的益处。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN H BERNSTEIN其他文献
STEVEN H BERNSTEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN H BERNSTEIN', 18)}}的其他基金
P- 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
P- 2:优化氧化还原调节作为 NHL 的治疗策略
- 批准号:
7507431 - 财政年份:2008
- 资助金额:
$ 30.84万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
7373337 - 财政年份:2008
- 资助金额:
$ 30.84万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
8260463 - 财政年份:2008
- 资助金额:
$ 30.84万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
7817051 - 财政年份:2008
- 资助金额:
$ 30.84万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
7628573 - 财政年份:2008
- 资助金额:
$ 30.84万 - 项目类别:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
项目 2:优化氧化还原调节作为 NHL 的治疗策略
- 批准号:
8131040 - 财政年份:
- 资助金额:
$ 30.84万 - 项目类别:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
项目 2:优化氧化还原调节作为 NHL 的治疗策略
- 批准号:
8381186 - 财政年份:
- 资助金额:
$ 30.84万 - 项目类别:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
项目 2:优化氧化还原调节作为 NHL 的治疗策略
- 批准号:
8321622 - 财政年份:
- 资助金额:
$ 30.84万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
Continuing Grant